Tumor Mucin Antigen (13-21)

Tumor Mucin Antigen (13-21) is a synthetic peptide fragment corresponding to amino acids 13 through 21 of a mucin-derived tumor-associated antigen sequence. As a well-characterized peptide epitope, it serves as a valuable molecular tool in the study of cancer-associated glycoproteins, particularly those implicated in tumor progression and immune recognition. The defined sequence allows for precise interrogation of antigenic determinants within mucin proteins, which are frequently overexpressed or aberrantly glycosylated in various malignancies. Its biochemical relevance extends to studies of tumor immunology, cellular signaling, and the development of peptide-based assays, making it an important reagent in cancer research and related fields.

Epitope Mapping: The peptide's defined sequence enables its use in detailed epitope mapping studies, where researchers seek to identify the specific regions of mucin antigens recognized by antibodies or immune cells. By incorporating this fragment into binding assays or immunoassays, scientists can elucidate the fine specificity of tumor-associated immune responses. Such studies are essential for characterizing monoclonal antibodies, understanding immune recognition patterns, and informing the rational design of targeted immunodiagnostics.

Antibody Screening and Validation: As a representative segment of a tumor mucin antigen, this peptide is widely employed in the screening and validation of antibody candidates. Researchers utilize it in enzyme-linked immunosorbent assays (ELISA), western blotting, and other immunodetection platforms to assess antibody binding specificity and affinity. The availability of a synthetic, sequence-defined peptide ensures reproducibility and accuracy in antibody development workflows, supporting both basic research and the generation of reliable immunoreagents.

Cancer Biomarker Discovery: The sequence motif encompassed by this peptide is relevant to the identification and characterization of tumor biomarkers. By serving as a molecular probe, it aids in the detection of mucin antigen expression in cancer cell lines, tissue samples, or biofluids. Its application in biomarker discovery platforms contributes to the differentiation of malignant and non-malignant samples, advancing the understanding of mucin's role in tumorigenesis and supporting the development of novel diagnostic approaches.

Peptide-Based Assay Development: The synthetic nature and defined structure of this peptide make it an excellent standard or control in the development of peptide-based assays. Researchers integrate it into multiplex immunoassays, peptide microarrays, and competitive binding studies to calibrate assay performance and validate analytical methods. Its stability and reproducibility facilitate the optimization of assay conditions, ensuring reliable detection of mucin-derived antigens in complex biological matrices.

T-Cell Response Studies: As a discrete antigenic determinant, this peptide can be utilized in studies focused on T-cell recognition and activation. By presenting the peptide in vitro to immune cells, investigators can assess T-cell specificity, cytokine production, and proliferative responses relevant to tumor immunity. These experiments are instrumental in dissecting the cellular immune mechanisms directed against mucin antigens and may inform the rational design of immunotherapeutic strategies or vaccine candidates for research purposes.

1. Myotropic activity of allatostatins in tenebrionid beetles

2. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

3. Quantitative Analysis of Ligands Effects on Bioefficacy of Nanoemulsion encapsulating Depigmenting Active

4. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry

5. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors